文献速递MDS 与骨髓增殖性肿瘤白血病

在持续接受芦可替尼治疗的真性红细胞增多症后或原发性血小板增多症后或原发性骨髓纤维化患者中加用纳维托克(REFINE):一项2期研究分子生物标志物的事后分析

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
PubMed 文献 · Lancet Haematol · 2022-05-13

REFINE研究1a队列事后分析显示,对芦可替尼单药治疗不再获益的骨髓纤维化患者,加用纳维托克后高分子风险组与非高分子风险组的脾脏体积缩小35%及以上(SVR35)比例均为31%,且纤维化改善或变异等位基因频率降低与总生存改善相关。

要点

  • 高分子风险组与非高分子风险组第24周SVR35比例均为31%。
  • 纤维化改善或变异等位基因频率降低20%及以上者总生存改善。
  • β-2微球蛋白等炎症因子变化与脾脏体积变化正相关。

核心结论

  • 对芦可替尼单药治疗不再获益的骨髓纤维化患者,加用纳维托克可获得独立于高分子风险突变状态的临床意义脾脏缓解。
  • 纤维化改善或变异等位基因频率降低者的总生存获益提示可能存在疾病修饰作用。

研究设计与样本

  • REFINE为2期多中心开放标签试验,评估纳维托克单药或联合芦可替尼治疗原发性或继发性骨髓纤维化的活性与安全性。
  • 1a队列纳入对稳定剂量芦可替尼单药治疗出现疾病进展或反应欠佳的患者,继续当前稳定剂量芦可替尼,纳维托克口服50 mg/日起始,按耐受性每周递增至最大300 mg/日。

主要发现

  • 2017年11月14日至2019年4月10日,1a队列34例患者接受至少一剂纳维托克联合芦可替尼;23例(68%)为男性,32例(94%)为白人。
  • 数据截止2021年5月6日,存活者中位随访26.2个月(IQR 21.9-32.3)。
  • 33例可评估生物标志物分析,19例(58%)具有高分子风险突变。
  • 高分子风险组16例中5例(31%)第24周达SVR35,非高分子风险组13例中4例(31%)达SVR35。
  • 高分子风险组11例中4例(36%)第24周达TSS50,非高分子风险组8例中2例(25%)达TSS50;高分子风险组18例中7例(39%)纤维化改善至少1级,非高分子风险组14例中5例(36%)改善至少1级;高分子风险组14例中4例(28%)变异等位基因频率降低20%及以上,非高分子风险组12例中2例(17%)降低20%及以上。

关键数值与推荐

  • β-2微球蛋白浓度变化与脾脏体积变化正相关(第12周r=0.57;第24周r=0.57)。
  • TIMP金属肽酶抑制剂1浓度变化与脾脏体积变化正相关(第12周r=0.47;第24周r=0.54)。
  • TNF受体II型浓度变化与脾脏体积变化正相关(第24周r=0.55;第24周r=0.40)。
  • 血管细胞黏附分子-1浓度变化与脾脏体积变化正相关(第24周r=0.58;第24周r=0.50)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary analyses of cohort 1a of the REFINE trial showed that addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolitinib. Here, we report the exploratory post-hoc biomarker analyses from cohort 1a. METHODS: REFINE is a phase 2, multicentre, open-label trial designed to assess the activity and safety of navitoclax alone or in combination with ruxolitinib in patients with primary or secondary (post-polycythaemia vera or post-essential thrombocythaemia) myelofibrosis. Cohort 1a of the study included patients who had disease progression or suboptimal response on stable ruxolitinib monotherapy. Patients in cohort 1a, who had previously received ruxolitinib for 12 weeks or more, continued their current stable dose, and navitoclax was orally administered at 50 mg per day and escalated weekly to a maximum of 300 mg per day, based on tolerability. The primary activity endpoint was SVR35 at week 24 from baseline. Secondary endpoints were a 50% or greater reduction in total symptom score (TSS50) at week 24 from baseline as measured by the Myelofibrosis Symptom Assessment Form (version 4.0), anaemia response assessed according to International Working Group-Myeloproliferative Neoplasms Research and European LeukemiaNet criteria, and change in grade of bone marrow fibrosis according to the European consensus grading system; and exploratory endpoints included overall survival and changes in inflammatory cytokines. Exploratory analyses investigated potential prognostic biomarkers of the benefit of navitoclax-based combination treatment, including bone marrow fibrosis and variant allele frequency, in patients with a suboptimal response to ruxolitinib. This study is registered with ClinicalTrials.gov (NCT03222609) and is ongoing. FINDINGS: Between Nov 14, 2017, and April 10, 2019, 34 patients in cohort 1a received at least one dose of navitoclax plus ruxolitinib. 23 (68%) patients were male, with 32 (94%) being White. At data cutoff (May 6, 2021), the median follow-up for survivors was 26·2 months (IQR 21·9-32·3). 33 patients were evaluable for biomarker analyses; 19 (58%) had high molecular risk mutations. Five (31%) of 16 patients had SVR35 at week 24 in the high molecular risk group, as did four (31%) of 13 in the non-high molecular risk group. Four (36%) of 11 patients in the high molecular risk group had TSS50 at week 24 compared with two (25%) of eight in the non-high molecular risk group; seven (39%) of 18 in the high molecular risk group had an improvement in fibrosis by at least one grade compared with five (36%) of 14 in the non-high molecular risk group; and four (28%) of 14 had reductions in variant allele frequency of 20% or greater in the high molecular risk group compared with two (17%) of 12 in the non-high molecular risk group. Patients with improvements in fibrosis of one grade or more and a reduction of 20% of more in variant allele frequency had improved overall survival (median overall survival not reached) compared with those who did not achieve fibrosis improvement or a reduction in variant allele frequency (median overall survival 28·5 months [95% CI 19·6-not estimable] for both), suggesting potential disease modification. Additionally, changes in concentrations of β-2-microglobulin (week 12: r=0·57; week 24: r=0·57), TIMP metallopeptidase inhibitor 1 (week 12: r=0·47; week 24: r=0·54), TNF receptor type II (r=0·55; week 24: r=0·40), and vascular cell adhesion molecule-1 (r=0·58; week 24: r=0·50) were positively associated with changes in spleen volume. INTERPRETATION: These biomarker analyses reveal clinically meaningful splenic responses independent of high molecular risk mutation status in patients treated with navitoclax plus ruxolitinib who were not benefiting from ruxolitinib monotherapy. Furthermore, the overall survival benefit observed in those with an improvement in fibrosis or a reduction in variant allele frequency is suggestive of disease modification, implying the therapeutic potential of adding navitoclax to ruxolitinib for patients with myelofibrosis who had disease progression or suboptimal response to ruxolitinib monotherapy. FUNDING: AbbVie.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Pemmaraju N, Garcia JS, Potluri J, et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 2022. PMID: 35576960. doi:10.1016/S2352-3026(22)00116-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。